BiomX Ltd (PHGE): Total Asset Value of Company

This price chart for BiomX Inc. (PHGE) total assets reflects a value of 33.33. Given the absence of revenue, expanding the project portfolio only increases the costs of maintaining the phage library. BiomX Inc. (PHGE) is developing antibiotic alternatives, leveraging successes in the treatment of cystic fibrosis and dermatology. Meanwhile, the business relies on external contractors and CROs, delegating synthesis and complex clinical trials to them.

Professional capital evaluates BiomX Inc. (PHGE) based on its ability to scale resources for the development of phage therapy for cystic fibrosis and dermatological pathologies. Total asset dynamics, calculated inversely via ROA, demonstrate the balance sheet's dependence on the cost of borrowed capital: asset expansion during low-rate periods accelerates R&D, yet excessive debt load during a cycle shift could undermine the issuer's financial stability.